Drug Profile
Tetanus vaccine oral - Acambis/Evans Vaccines
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Acambis
- Developer Acambis; Evans Vaccines
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Tetanus
Most Recent Events
- 25 Sep 2008 Acambis has been acquired by sanofi pasteur
- 24 Oct 2000 PowderJect Pharmaceuticals has acquired Medeva's vaccines business from Celltech and now calls it Evans Vaccines
- 26 Feb 1998 Suspended-Preclinical for Tetanus in United Kingdom (PO)